Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Avricore Health (AVCRF) Research & Development (2016 - 2025)

Avricore Health has reported Research & Development over the past 10 years, most recently at $8693.5 for Q3 2025.

  • Quarterly Research & Development rose 1247.64% to $8693.5 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $99909.1 through Sep 2025, up 317.62% year-over-year, with the annual reading at $69634.8 for FY2024, 166.03% up from the prior year.
  • Research & Development was $8693.5 for Q3 2025 at Avricore Health, down from $16206.1 in the prior quarter.
  • Over five years, Research & Development peaked at $43021.1 in Q4 2024 and troughed at $645.09 in Q3 2024.
  • The 3-year median for Research & Development is $16206.1 (2025), against an average of $17514.5.
  • Year-over-year, Research & Development crashed 43.43% in 2021 and then skyrocketed 1247.64% in 2025.
  • A 3-year view of Research & Development shows it stood at $696.38 in 2021, then soared by 6077.83% to $43021.1 in 2024, then plummeted by 79.79% to $8693.5 in 2025.
  • Per Business Quant, the three most recent readings for AVCRF's Research & Development are $8693.5 (Q3 2025), $16206.1 (Q2 2025), and $31988.5 (Q1 2025).